Prostamax (20 mg Vial) Dosage Protocol
Prostamax is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro / KEDP) derived from prostate tissue peptide complex research. Short peptides of this class are studied for their ability to modulate gene expression through epigenetic interactions with chromatin and histones.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Intramuscular (or subcutaneous alternative) | Frequency: Once daily | Half-life: Short; cumulative cycle effect
Standard Approach (2 mL = 10.00 mg/mL)
Reconstituting with 2 mL bacteriostatic water produces a concentration of 10.00 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 500 mcg | 5 units | 0.050 mL | 40 doses |
| Weeks 3–4 | 750 mcg | 7.5 units | 0.075 mL | 26 doses |
| Weeks 5–8 (target) | 1 mg | 10 units | 0.10 mL | 20 doses |
| Weeks 9–12 (optional) | 1 mg | 10 units | 0.10 mL | 20 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 2 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 14 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 1 mg per dose, once daily (7 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| Prostamax (20 mg) vials | 3 vials | 5 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 1 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
This peptide bioregulator follows the standard Khavinson-class cycle protocol — 10–20 day intensive cycles, 1–2 times per year. The hypothesized gene-expression mechanism produces effects that persist months after the cycle ends, supporting the cycled rather than continuous approach.
Dosing Protocol
Cycle-based dosing:
- Standard cycle: Daily dose during 10–20 day active phase, 5–6 month break.
Cycle structure: 1–2 cycles per year. Some users align cycles with seasonal transitions.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins. In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes. Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue.
Potential Benefits & Side Effects
Potential Benefits
- Reduced inflammation in rat prostatitis models (IM, 15–60 day treatment).
- Favorable effects on prostate weight and histology in BPH models.
- Short bioregulatory peptides of this class show favorable tolerability in preclinical work.
Side Effect Profile
- Generally well-tolerated in preclinical studies; no published human trials.
- Mild injection-site reactions (redness, tenderness) possible with IM administration.
Lifestyle Factors
- Maintain balanced diet rich in vegetables, healthy fats, and adequate protein.
- Regular physical activity supports circulation and prostate health.
- Adequate hydration; limit alcohol/caffeine may support urinary function.
- Prioritize sleep and stress management.
Injection Technique
- Intramuscular into large muscle group (deltoid, vastus lateralis, or gluteus); 22–25 gauge, 1–1.5 inch needle at 90°.
- Aspiration before IM injection is no longer routinely recommended for most sites.
- Rotate sites systematically to avoid muscle irritation or fibrosis.
- Subcutaneous alternative: 23–25 gauge 5/8 inch needle at 45° into fatty tissue.